Analyst firms · Morgan Stanley · HOLX
Morgan Stanley HOLX price target and rating history
Hologic Inc. (HOLX) · Health Care
Morgan Stanley rates Hologic Inc. (HOLX) Equal-Weight with a $75 price target, as of its latest action on Feb 3, 2022. It has published 3 rating actions on HOLX since July 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $75
- Median target, all firms
- Too few
- Actions on HOLX
- 3
Morgan Stanley price target on HOLX
Every Morgan Stanley rating on HOLX
- Feb 3, 2022
- Nov 2, 2021
- Jul 30, 2021
How other firms rate HOLX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Hold | Jan 12, 2026 | |
| Evercore ISI | In-line | $78 | Jan 5, 2026 |
| BNP Paribas Exane | Neutral | $79 | Nov 21, 2025 |
Questions about Morgan Stanley and HOLX
- What is Morgan Stanley's price target for HOLX?
- Morgan Stanley's latest stated price target for Hologic Inc. (HOLX) is $75, from its action on Feb 3, 2022.
- What is Morgan Stanley's rating on HOLX?
- Morgan Stanley rates HOLX Equal-Weight, a neutral rating, as of Feb 3, 2022.
- When did Morgan Stanley last change its view on HOLX?
- On Feb 3, 2022, Morgan Stanley cuts its price target to $75 from $76, keeps Equal-Weight.
More HOLX rating histories
All Morgan Stanley ratingsHOLX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.